Intranasal delivery of peptide compounds can bypass the blood-brain barrier to directly affect brain neurotransmitter systems, offering a promising route for treating psychiatric and neurodegenerative diseases.
Bypasses the blood-brain barrierIntranasal peptide delivery uses direct nerve pathways from nose to brain, avoiding the blood-brain barrier that blocks most peptide drugs from reaching their target
What the researchers found
Intranasal delivery of amino acid and peptide-based compounds can effectively reach the brain's monoamine systems (dopamine, serotonin, norepinephrine) by bypassing the blood-brain barrier through the nose-to-brain pathway. This review synthesizes experimental evidence showing that nasally administered peptides can modulate neurotransmitter systems relevant to psychiatric and neurodegenerative diseases.
The nose-to-brain route exploits direct neural connections (primarily the olfactory and trigeminal nerves) to transport peptide drugs from the nasal cavity to the central nervous system, avoiding both the blood-brain barrier and first-pass liver metabolism. The approach shows promise for conditions including schizophrenia, depression, anxiety, ADHD, Alzheimer's disease, and Parkinson's disease.
Why it matters
Most peptide drugs cannot cross the blood-brain barrier, which has been the biggest obstacle to using peptides for brain diseases. Intranasal delivery offers a non-invasive workaround that could unlock peptide therapies for millions of people with psychiatric and neurodegenerative conditions. The growing burden of these diseases worldwide makes finding effective brain-targeted delivery methods increasingly urgent.
The numbers in context
Nose-to-brain pathway bypasses BBB + liver · Targets: dopamine, serotonin, norepinephrine systems · Potential applications: schizophrenia, depression, anxiety, ADHD, Alzheimer's, Parkinson's
How the study worked
Narrative review of experimental studies on intranasal delivery of amino acid and peptide compounds to the brain, focusing on transport mechanisms via the nose-to-brain projection and therapeutic efficacy on monoamine neurotransmitter systems. Published in Georgian Medical News.
Who was studied
Not applicable (review of experimental/preclinical studies on intranasal peptide delivery)
What this study cannot tell us
Published in Georgian Medical News, a lower-impact journal. The abstract is quite general and doesn't provide specific data on any individual peptide or clinical outcome. Most evidence discussed is likely preclinical (animal studies). The review doesn't address key practical challenges like nasal irritation, dose consistency, or regulatory hurdles for intranasal peptide products.
How to read the evidence
Published in Georgian Medical News, a lower-impact journal. The review provides a useful overview of the nose-to-brain delivery concept but the abstract lacks specific experimental data. Most underlying evidence is likely preclinical.
When this study was published
Published in 2024. Reflects current thinking on intranasal peptide delivery, an area of active research with growing clinical interest.
The bigger picture
Intranasal peptide delivery is one of the most active areas in drug delivery research. If perfected, it could transform how we treat brain diseases — turning peptides that currently can't reach the brain into effective neurological medications. Several intranasal peptide products (like oxytocin nasal spray) already exist, and this review points toward a much broader future where nasal peptide formulations could address conditions from depression to dementia.
Questions still open
- Which specific peptides have shown the most promising nose-to-brain delivery results in preclinical studies?
- How consistent is nasal peptide absorption across individuals, given differences in nasal anatomy and health?
- Could intranasal peptide delivery eventually replace injectable peptides for brain-targeted conditions?
Common questions
How can peptides get from your nose to your brain?
Are there already nasal peptide drugs available?
Read the original research
THE EFFECT OF INTRANASAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES OF AMINO ACID AND PEPTIDE NATURE ON THE MONOAMINE SYSTEMS OF THE BRAIN.
Georgian medical news, 55-67
Citation
Apryatin, S; Moiseenko, V; Gainetdinov, R; Apryatina, V. (2024). THE EFFECT OF INTRANASAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES OF AMINO ACID AND PEPTIDE NATURE ON THE MONOAMINE SYSTEMS OF THE BRAIN.. Georgian medical news, 55-67.